Wednesday, February 24, 2016

Forty Seven Finds $32.5M For Cancer Antibodies

Palo Alto-based Forty Seven Inc., which is developing antibodies aimed at attacking cancer tumors, has raised the first half of a $75M in a Series A financing, the company said today. The company said the Series A was led by Lightspeed Venture Partners and Sutter Hill Ventures along with Clarus Ventures and GV (formerly Google Ventures). The company has licensned imuno-oncology programs from Stanford. The company's lead compound is Hu5F9-G4, a humanized monoclonal antibody against human CD47 that the company says has broad applications spanning multiple tumor types and treatment modalities. More information »